Mereo BioPharma draws eyes ahead of Jefferies Healthcare talk
Mereo BioPharma’s U.S. shares traded at $0.3342 in premarket Thursday, down $0.0104, as investors awaited CEO Denise Scots-Knight’s appearance at the Jefferies Global Healthcare Conference. The company’s setrusumab drug missed main fracture-reduction goals in Phase 3 trials but met secondary bone-density targets. Mereo reported $36.2 million in cash at March 31 and projects funding into mid-2027.